Format

Send to

Choose Destination
Nat Biotechnol. 2014 Aug;32(8):742-8. doi: 10.1038/nbt.2975.

The global intellectual property landscape of induced pluripotent stem cell technologies.

Author information

1
Oxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK.
2
1] Oxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK. [2] Department of Biochemical Engineering, University College London, London, UK. [3] Department of Nanobiomedical Science and BK21 Plus NBM, Global Research Center of Regenerative Medicine, Dankook University, Cheonan, Republic of Korea. [4] Biomaterials and Tissue Engineering Lab, Department of Nanobiomedical Science and World Class University Research Center, Dankook University, Cheonan, Republic of Korea.
3
IP Asset LLP, Oxford, UK.
4
The Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
5
Sartorius Stedim, Göttingen, Germany.
6
1] Oxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK. [2].
7
1] Oxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK. [2] The Harvard Stem Cell Institute, Cambridge, Massachusetts, USA. [3] Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, UK. [4] Centre for Behavioural Medicine, UCL School of Pharmacy, University College London, London, UK. [5].
PMID:
25093884
DOI:
10.1038/nbt.2975
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center